Regeneron Maintains Its Momentum During Pandemic

 
• By Jessica Merrill

The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.

SC2005_Momentum_492748873_1200.jpg
Regeneron reported a solid first quarter • Source: Shutterstock

More from Earnings

More from Business